Cancer Family
B-Cell Malignant Neoplasm
CI-CAN-00000070Explore in graph →
Hematologic2,083 active trials46 approved drugs301 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000070Explore in graph →
Clinical trials
7,465 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,167)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06314828 | A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL | not yet recruiting | Phase 1 | 30 | Guangdong Ruishun Biotech Co., LtdINDUSTRY | 0 | Mar 18, 2024 | clinicaltrials |
| NCT06232096 | A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. | recruiting | Phase 1 / Phase 2 | 154 | Beijing Mabworks Biotech Co., Ltd.INDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06298266 | To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma | not yet recruiting | Early Phase 1 | 15 | Guangdong Second Provincial General HospitalOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT03131531 | Bergamo Lymphoid Cancer Registry | recruiting | — | 6,000 | A.O. Ospedale Papa Giovanni XXIIIOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04144387 | Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.(CARRISMM) | active not recruiting | N/A | 395 | Intergroupe Francophone du MyelomeNETWORK | 3 | Mar 6, 2024 | clinicaltrials |
| NCT06286228 | Registry of Haploidentical Hematopoietic Stem Cell Transplantation in Adult With Hematologic Disease(Haplo) | not yet recruiting | — | 43 | Siriraj HospitalOTHER | 0 | Mar 1, 2024 | clinicaltrials |
| NCT04210791 | Autologous Stem Cell Transplantation for Patients With AL Amyloidosis | enrolling by invitation | — | 500 | Nanjing University School of MedicineOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06279026 | UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma | recruiting | N/A | 15 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06228963 | Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma | recruiting | Phase 2 | 160 | Fudan UniversityOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT03620578 | DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL(HO152) | active not recruiting | Phase 2 | 97 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 2 | Feb 14, 2024 | clinicaltrials |
| NCT06255704 | A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients(Z+RCHOP/RDHAP) | not yet recruiting | Phase 2 | 23 | Shanxi Province Cancer HospitalOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT05214183 | Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma(ALTAMIRA) | active not recruiting | Phase 2 | 81 | Nordic Lymphoma GroupNETWORK | 5 | Feb 12, 2024 | clinicaltrials |
| NCT06250595 | European Rare Blood Disorders Platform (ENROL)(ENROL) | recruiting | — | 37,090 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT06246162 | Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 30 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05243212 | Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 75 | Sheba Medical CenterOTHER_GOV | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06220487 | A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL(ABC) | recruiting | Phase 2 | 67 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT05246345 | Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia(RAVEN) | recruiting | — | 50 | University Hospital, Clermont-FerrandOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT06196255 | Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05833763 | A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.(GOlDiLOX) | recruiting | Phase 2 | 42 | Australasian Leukaemia and Lymphoma GroupOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT06180174 | Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma | recruiting | Phase 1 | 24 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Dec 28, 2023 | clinicaltrials |
| NCT06176729 | Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients | recruiting | Phase 2 | 30 | Yan Zhang, MDOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT03915184 | Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2) | active not recruiting | Phase 1 / Phase 2 | 105 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 2 | Dec 19, 2023 | clinicaltrials |
| NCT06175702 | Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL(LALPh2022) | not yet recruiting | — | 150 | PETHEMA FoundationOTHER | 0 | Dec 19, 2023 | clinicaltrials |
| NCT03289299 | Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant(ASCENT) | active not recruiting | Phase 2 | 87 | International Myeloma FoundationOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT06158269 | DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma | recruiting | Phase 2 | 40 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT06154902 | Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel(ABE-DESCART) | active not recruiting | — | 350 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 4, 2023 | clinicaltrials |
| NCT05694312 | Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL | recruiting | Phase 2 | 45 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT04718883 | CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma | active not recruiting | Phase 2 | 59 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT06039735 | Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple Myeloma | recruiting | — | 50 | Qilu Hospital of Shandong UniversityOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT06142188 | Relmacabtagene Autoleucel in Hematologic Malignancies | not yet recruiting | — | 150 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT06132711 | Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma(CAR-T) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT03110822 | A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients | recruiting | Phase 1 | 134 | OncotherapeuticsINDUSTRY | 1 | Nov 1, 2023 | clinicaltrials |
| NCT03673826 | Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM(HO147SMM) | active not recruiting | Phase 2 | 58 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 4 | Nov 1, 2023 | clinicaltrials |
| NCT05849857 | Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries(MERLIN) | recruiting | Phase 2 | 80 | Oslo University HospitalOTHER | 2 | Nov 1, 2023 | clinicaltrials |
| NCT04808037 | Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma(BelaRd) | active not recruiting | Phase 1 / Phase 2 | 66 | Hellenic Society of HematologyOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT05573802 | A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 36 | Hellenic Society of HematologyOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT05923502 | (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL) | not yet recruiting | — | 200 | Ruijin HospitalOTHER | 0 | Oct 23, 2023 | clinicaltrials |
| NCT04349358 | FCH vs FDG PET/CT in Detection of Lesions in Patients With Multiple Myeloma (MIM)(MIM) | recruiting | N/A | 38 | Centre Georges Francois LeclercOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06084962 | A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma | recruiting | Phase 1 | 40 | He HuangOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT06081478 | CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 100 | Beijing Tongren HospitalOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT04558931 | Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma | recruiting | Phase 2 | 62 | Karolinska InstitutetOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT04758975 | Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)(VALUABLE) | recruiting | Phase 2 | 55 | Paolo GhiaOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT06065852 | National Registry of Rare Kidney Diseases(RaDaR) | recruiting | — | 35,000 | UK Kidney AssociationOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT04790045 | Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens(LymBIO) | not yet recruiting | Phase 4 | 30 | Paolo GhiaOTHER | 0 | Oct 3, 2023 | clinicaltrials |
| NCT04908228 | Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL(FIGHT) | recruiting | Phase 2 | 53 | Paolo GhiaOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT06049472 | Patient Perspectives in Mantle Cell Lymphoma Clinical Research | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Sep 22, 2023 | clinicaltrials |
| NCT06049485 | Assessing the Experience of Patients Undergoing Follicular Lymphoma Clinical Research | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Sep 22, 2023 | clinicaltrials |
| NCT06045091 | To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL | recruiting | Early Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04613557 | Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma(IMMUNICY-1) | active not recruiting | Phase 1 | 18 | Celyad Oncology SAINDUSTRY | 2 | Aug 31, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Mar 18, 2024source: clinicaltrials